Clinical Trials

DISEASE CHARACTERISTICS:

• Biopsy-proven (consisting of ≥ 10 tissue cores) adenocarcinoma of the prostate diagnosed within 24 months prior to presentation
  • < 25% of biopsy tissue cores positive for cancer
  • ≤ 50% of any one biopsy tissue core positive for cancer
• Clinical stage ≤ T2a
• Patients who have prostate cancer with distant metastases are not eligible
• For men ≤ 70 years, biopsy Gleason score ≤ 6; for men > 70 years, biopsy Gleason score ≤ (3 + 4) = 7
• Serum PSA < 10 ng/mL
  • Baseline PSA for determination of eligibility must be measured after discontinuation of any 5-alpha reductase inhibitors
• Patients are offered registration to the correlative study CALGB-151105

PATIENT CHARACTERISTICS:

• Life expectancy of at least 3 years
• Patients must be able to read and comprehend English language text and be able to understand spoken English over the phone
• Patients who have had a history of non-cutaneous malignancy (other than nonmelanoma skin cancer) in the previous 5 years are not eligible
• Successful completion of three 24-hour dietary recalls during the run-in period

PRIOR CONCURRENT THERAPY:

• Patients who have had prior treatment for prostate cancer by surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy are not eligible
• Patients who are currently taking vitamin supplements including lycopene and beta-carotene are eligible
• Patients who are currently taking coumadin are not eligible
• Patients consuming ≥ 6 servings per day of fruits and vegetables (not including juices), as measured by the run-in dietary recalls, are not eligible
• Patients receiving treatment with 5-alpha reductase inhibitors within 90 days prior to preregistration are not eligible